Oral Contraceptive Pill and GnRH Antagonist Versus Long Protocol in IVF Patients

Recent controversy has arisen regarding the use of the pill for cycle planning in GnRH antagonist IVF cycles. The investigators performed this study to compare such a protocol with the gold-standard still today, which is the long-agonist protocol with no previous use of the pill.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility Genital Diseases Urogenital Diseases

Age range

18 year–38 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Instituto Valenciano de Infertilidad

Madrid, 28035, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

1st or 2nd IVF cycle
BMI <30 kg/m2
regular menstrual cycles
basal FSH <10 IU and E2 <60 pg/ml

Exclusion criteria

Polycystic ovaries
endometriosis
previous ovarian surgery
previous low ovarian response

Treatment and study plan

levonorgestrel and ethynilestradiol

Drug

Primary outcomes

implantation rate

Time frame: 2 weeks after the embryo transfer

Sponsors and collaborators

Lead sponsor

IVI Madrid

Other

Registry information

Official study title

Cycle Planning With OCP in GnRH Antagonists Cycles Versus Long Protocol in Good Prognosis IVF Patients

Acronym: Larganta

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2010
First posted: Jul 7, 2010
Registry last updated: Apr 22, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed